Intact B7‐H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses
- 5 September 2012
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 42 (9) , 2343-2353
Abstract
Ligands of the B7 family provide both positive and negative costimulatory signals to the CD28 family of receptors on T lymphocytes, the balance of which determines the immune response. B7‐H3 is a member of the B7 family whose function in T‐cell activation has been the subject of some controversy: in autoimmunity and tumor immunity, it has been described as both costimulatory and coinhibitory, while in transplantation, B7‐H3 signaling is thought to contribute to graft rejection. However, we now demonstrate results to the contrary. Signaling through a putative B7‐H3 receptor prolonged allograft survival in a fully MHC‐mismatched cardiac model and promoted a shift toward a Th2 milieu; conversely, B7‐H3 blockade, achieved by use of a blocking antibody, resulted in accelerated rejection, an effect associated with enhanced IFN‐γ production. Finally, graft prolongation achieved by CTLA4 Ig was shortened both by B7‐H3 blockade and the absence of recipient B7‐H3. These findings suggest a coinhibitory role for B7‐H3. However, experience with other CD28/B7 family members suggests that immune redundancy plays a crucial role in determining the functions of various pathways. Given the abundance of conflicting data, it is plausible that, under differing conditions, B7‐H3 may have both positive and negative costimulatory functions.Keywords
This publication has 30 references indexed in Scilit:
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Unexpected Acceleration of Type 1 Diabetes by Transgenic Expression of B7-H1 in NOD Mouse Peri-Islet GliaDiabetes, 2010
- Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasLaboratory Investigation, 2010
- B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interactionEuropean Journal of Immunology, 2009
- Fine tuning the immune response through B7‐H3 and B7‐H4Immunological Reviews, 2009
- Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responsesProceedings of the National Academy of Sciences, 2008
- Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serumImmunology, 2008
- B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcomeProceedings of the National Academy of Sciences, 2007
- B7‐H3 promotes acute and chronic allograft rejectionEuropean Journal of Immunology, 2005
- The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responsesNature Immunology, 2003